Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
ID | DOID:111147 |
Name | angioimmunoblastic T-cell lymphoma |
Definition | A peripheral T-cell lymphoma characterized by autoimmune features and poor prognosis. |
Source | DiseaseOntology.org |
Alt Ids | |
Path | disease disease of cellular proliferation cancer organ system cancer hematologic cancer lymphoma non-Hodgkin lymphoma mature T-cell and NK-cell lymphoma peripheral T-cell lymphoma angioimmunoblastic T-cell lymphoma |
Molecular Profile | Therapy | Indication/Tumor Type | Response Type | Profile Response Detail |
---|---|---|---|---|
Unknown unknown | Domatinostat | angioimmunoblastic T-cell lymphoma | not applicable | detail... |
TET2 mutant | N/A | angioimmunoblastic T-cell lymphoma | not applicable | detail... |
DNMT3A mutant | N/A | angioimmunoblastic T-cell lymphoma | not applicable | detail... |
IDH2 mutant | N/A | angioimmunoblastic T-cell lymphoma | not applicable | detail... |
IDH1 mutant | N/A | angioimmunoblastic T-cell lymphoma | not applicable | detail... |
TET2 T1063Nfs*5 TET2 E1207K | Dasatinib | angioimmunoblastic T-cell lymphoma | predicted - sensitive | detail... |
Unknown unknown | AZD4573 | angioimmunoblastic T-cell lymphoma | not applicable | detail... |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT02232516 | Phase II | Lenalidomide + Romidepsin | Romidepsin and Lenalidomide in Treating Patients With Previously Untreated Peripheral T-Cell Lymphoma | Recruiting | USA | 0 |
NCT02689453 | Phase I | Alemtuzumab + rhIL-15 | Subcutaneous Recombinant Human IL-15 (s.c. rhIL-15) and Alemtuzumab for People With Refractory or Relapsed Chronic and Acute Adult T-cell Leukemia (ATL) | Active, not recruiting | USA | 0 |
NCT03017820 | Phase I | VSV-hIFNbeta-NIS | VSV-hIFNbeta-NIS in Treating Patients With Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia, or T-cell Lymphoma | Recruiting | USA | 0 |
NCT03049449 | Phase I | ATLCAR.CD30 cells Cyclophosphamide + Fludarabine | T Cells Expressing a Fully-Human Anti-CD30 Chimeric Antigen Receptor for Treating CD30-Expressing Lymphomas | Recruiting | USA | 0 |
NCT03081910 | Phase I | CD5 CAR T cells Cyclophosphamide + Fludarabine | Autologous T-Cells Expressing a Second Generation CAR for Treatment of T-Cell Malignancies Expressing CD5 Antigen (MAGENTA) | Recruiting | USA | 0 |
NCT03372057 | Phase II | Duvelisib | A Study of Duvelisib in Patients With Relapsed or Refractory Peripheral T Cell Lymphoma (PTCL) | Recruiting | USA | 3 |
NCT03586999 | Phase Ib/II | Cyclophosphamide + Doxorubicin + Etoposide + Nivolumab + Prednisone + Vincristine Sulfate | Nivolumab With Standard of Care Chemotherapy for Peripheral T Cell Lymphomas | Recruiting | USA | 0 |
NCT03719105 | Phase I | Pembrolizumab Brentuximab vedotin + Cyclophosphamide + Doxorubicin + Pralatrexate + Prednisone Calaspargase pegol-mknl + Dexamethasone + Etoposide + Ifosfamide + Methotrexate | Chemoimmunotherapy and Allogeneic Stem Cell Transplant for NK T-cell Leukemia/Lymphoma | Recruiting | USA | 0 |
NCT03829540 | Phase I | CD4CAR | CD4CAR for CD4+ Leukemia and Lymphoma | Recruiting | USA | 0 |
NCT03902184 | Phase II | Gemcitabine + Lacutamab + Oxaliplatin Lacutamab | IPH4102 Alone or in Combination With Chemotherapy in Patients With Advanced T Cell Lymphoma (TELLOMAK) | Recruiting | USA | 5 |
NCT04234048 | Phase I | Fenretinide | Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma | Not yet recruiting | USA | 0 |
NCT04639843 | Phase I | Azacitidine + Doxorubicin + Duvelisib + Romidepsin | Doxorubicin, CC-(486) (5-azacitidine), Romidepsin, and Duvelisib (hARD) for T-cell Lymphoma | Not yet recruiting | USA | 0 |
NCT04747236 | Phase II | Pralatrexate Belinostat Azacitidine + Romidepsin Gemcitabine Romidepsin | A Randomized, Phase IIB, Multicenter, Trial of Oral Azacytidine Plus Romidepsin Versus Investigator's Choice in Patients With Relapse or Refractory Peripheral T-cell Lymphoma (PTCL) | Not yet recruiting | USA | 0 |